Corrigendum to "1,4-Dihydroindeno[1,2-c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors" [Bioorg. Med. Chem. Lett. 16 (2006) 4266-4271] (DOI:10.1016/j.bmcl.2006.05.066);1,4-Dihydroindeno[1,2-c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 16, 2006, Pages 4266-4271

  Dinges, Jürgen ^a   Ashworth, Kimba L ^a   Akritopolou Zanze, Irini ^a   Arnold, Lee D ^b   Baumeister, Steven A ^a   Bousquet, Peter F ^a   Cunha, George A ^a   Davidsen, Steven K ^a   Djuric, Stevan W ^a   Gracias, Vijaya J ^a   Michaelides, Michael R ^a   Rafferty, Paul ^a   Sowin, Thomas J ^a   Stewart, Kent D ^a   Xia, Zhiren ^a   Zhang, Henry Q ^a  

^a ABBOTT LABORATORIES   (United States)

^b OSI PHARMACEUTICALS INC   (United States)

Author keywords

1,4 Dihydroindeno 1,2 c pyrazole; Cancer; Inhibitor; KDR kinase; Receptor tyrosine kinase

Indexed keywords

1,4 DIHYDROINDENO[1,2 C]PYRAZOLE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; THIOPHENE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ARTICLE; DRUG IDENTIFICATION; DRUG TARGETING; ENZYME SPECIFICITY; HYDROPHOBICITY;

EID: 33745699182     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.05.001     Document Type: Erratum

References (15)

1. Reilly J.T. Br. J. Hematol. 116 (2002) 744
2. Hannah A.L. Curr. Mol. Med. 5 (2005) 625
3. Jansen M., de Witt Hamer P.C., Witmer A.N., Troost D., and van Noorden C.J.F. Brain Res. Rev. 45 (2004) 143
4. Carlomagno F., and Santoro M. Curr. Med. Chem. 12 (2005) 1773
5. Krystal G.W., Hines S.J., and Organ C.P. Cancer Res. 56 (1996) 370
6. Garton A.J., Crew A.P.A., Franklin M., Cooke A.R., Wynne G.M., Castaldo L., Kahler J., Winski S.L., Franks A., Brown E.N., Bittner M.A., Keily J.F., Briner P., Hidden C., Srebernak M.C., Pirrit C., O'Connor M., Chan A., Vulevic B., Henninger D., Hart K., Sennello R., Li A.H., Zhang T., Richardson F., Emerson D.L., Castelhano A.L., Arnold L.D., and Gibson N.W. Cancer Res. 66 (2006) 1015
7. Dinges, J.; Akritopoulou-Zanze, A.; Arnold, L. D.; Barlozzari, T.; Bousquet, P. F.; Cunha, G. A.; Ericsson, A. M.; Iwasaki, N.; Michaelides, M. R.; Ogawa, N.; Phelan, K. M.; Rafferty, P.; Sowin, T. J.; Stewart, K. D.; Tokuyama, R.; Xia, Z.; Zhang, H. Q. Bioorg. Med. Chem. Lett. in press, doi:10.1016/j.bmcl.2006.05.052.
8. Tang W., Wang R.W., and Lu A.Y.H. Curr. Drug Metabol. 6 (2005) 503
9. For structural studies on urea-type KDR inhibitors and for a detailed description of all biological assays, see:. Dai Y., Guo Y., Frey R.R., Ji Z., Curtin M.L., Ahmed A.A., Albert D.H., Arnold L., Arries S.S., Barlozzari T., Bauch J.L., Bouska J.J., Bousquet P.F., Cunha G.A., Glaser K.B., Guo J., Li J., Marcotte P.A., Marsh K.C., Moskey M.D., Pease L.J., Stewart K.D., Stoll V.S., Tapang P., Wishart N., Davidsen S.K., and Michaelides M.R. J. Med. Chem. 48 (2005) 6066
10. Miyazaki Y., Matsungaga S., Tang J., Maeda Y., Nakano M., Philippe R.J., Shibahara M., Liu W., Sato H., Wang L., and Nolte R.T. Bioorg. Med. Chem. Lett. 15 (2005) 2203
11. Dumas J., Smith R.A., and Lowinger T.B. Curr. Opin. Drug Discovery Dev. 7 (2004) 600
12. Mol C.D., Dougan D.R., Schneider T.R., Skene R.J., Kraus M.L., Scheibe D.N., Snell G.P., Zou H., Sang B.C., and Wilson K.P. J. Biol. Chem. 279 (2004) 31655
13. Thompson A.S., Humphrey G.R., DeMarco A.M., Mathre D.J., and Grabowski E.J.J. J. Org. Chem. 58 (1993) 5886
14. The synthesis of these compounds is described in: Makoto, A.; Arnold, L. D.; Dinges, J.; Dixon, R. W.; Djuric, S. W.; Ericsson, A. M.; Fischer, K.; Gasiecki, A. F.; Gracias, V. J.; Holms, J. H.; Michaelides, M. R.; Muckey, M. A.; Rafferty, P.; Steinman, D. H.; Wada, C. K.; Xia, Z.; Akritopoulou-Zanze, I.; Zhang, H. Q. Int. Pat. Appl. WO 095387, 2005; Chem. Abstr. 2005, 143, 387029.
15. Kobayashi H., and Lin P.C. Front. Biosci. 10 (2005) 666